Advanced modification of drug nanocrystals by using novel fabrication and downstream approaches for tailor-made drug delivery

Tao Liu\(^a\), Xinxin Yu\(^a\), Haipeng Yin\(^b\) and Jan P. Möschwitzer\(^c\)

\(^a\)Department of Pharmaceutical Engineering, Qingdao University of Science and Technology, Qingdao, China; \(^b\)Department of Internal Medicine, Qingdao orthopaedic Hospital, Qingdao, China; \(^c\)Institute of Pharmacy, Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics, Freie Universität Berlin, Berlin, Germany

**ABSTRACT**

Drug nanosuspensions/nanocrystals have been recognized as one useful and successful approach for drug delivery. Drug nanocrystals could be further decorated to possess extended functions (such as controlled release) and designed for special in vivo applications (such as drug tracking), which make best use of the advantages of drug nanocrystals. A lot of novel and advanced size reduction methods have been invented recently for special drug deliveries. In addition, some novel downstream processes have been combined with nanosuspensions, which have highly broadened its application areas (such as targeting) besides traditional routes. A large number of recent research publication regarding as nanocrystals focuses on above mentioned aspects, which have widely attracted attention. This review will focus on the recent development of nanocrystals and give an overview of regarding modification of nanocrystal by some new approaches for tailor-made drug delivery.

**1. Introduction**

Drug nanosuspensions, often referred to as drug nanocrystals, can be considered as one of the most successful pharmaceutical nanotechnology approach. Nanocrystal technology has gone through nearly 30 years of evolutionary improvement since it was firstly invented in 1991 (Muller & Keck, 2012). To date, an increasing number of novel advanced preparation methods and downstream technologies have been developed for tailor-made drug delivery. Consequently, the drug nanocrystal preparation efficiency has been improved and its functional characters have also been highly extended.

Regarding the preparation methods, the top-down (high pressure homogenization and wet bead milling) and bottom-up (solvent antisolvent precipitation) methods are still the most frequently used preparation approaches (Liu et al., 2015; Gigliobianco et al., 2018; Malamaturi et al., 2018; Miao et al., 2018). Some novel technologies have been invented recently, which possessed the capability to produce smaller nanoparticle sizes (e.g., <100 nm) (Li et al., 2015), improve the production efficiency (Liu et al., 2016) or achieve pure drug nanoparticles of amorphous active pharmaceutical ingredients (APIs) (Guo et al., 2013). Most of the new invented technologies are still based on the top-down or bottom-up approaches.

Drug nanosuspension is a relatively “simple” system, which is consisted of only API dispersed in aqueous stabilizer solutions (Peltonen & Hirvonen, 2018). Although just a particle size reduction into the nanometer range can by itself lead to a faster dissolution rate or a higher saturation solubility compared to microsized API, this technology normally cannot possess advantages such as targeting compared to other nanocarrier systems. Most recently, a lot of research groups have started to use downstream processes to broaden its capabilities and applications. Drug nanocrystals have been decorated to further possess advanced in vitro and in vivo performances based on the specific requirement of drug delivery.

This review will mainly focus on the most recent development of drug nanocrystals regarding as novel specific aims of drug delivery or modified in vitro as well as in vivo performances based on some new preparation technologies or downstream processes (Figure 1), as most research publication in recent years about drug nanocrystals are correlated to those aspects (Table 1).

**2. Tailor-made drug delivery based on nanocrystals**

**2.1. Ultra-small particle size for fast drug release**

Top-down and bottom-up technologies are the two fundamental approaches for nanocrystal production, which normally lead to particle size in the range of 100 nm–1000 nm. Besides standard top-down and bottom-up methods, this review gives a summary of some recent improved or
advanced technologies for ultra-small particle size, i.e. <100 nm.

Wet bead milling (WBM) and high pressure homogenization (HPH) are the two main top-down approaches. WBM uses milling machine to rotate the small milling bead/ball either by an agitator blade or by stirring of the whole sample container. For HPH, the high pressure homogenizer can be divided in two main types: piston-gap and jet-stream. Mechanisms of both have been detailed discussed in many related review papers (Van Eerdenbrugh et al., 2008; Liu et al., 2015; Fontana et al., 2018; Jermain et al., 2018; Couillaud et al., 2019; Pardhi et al., 2019). Normally, no organic solvent is required during the production process compared to the bottom-up processes. However, the substitution of water could be acceptable for some specific purposes (Zhai et al., 2014).

By far, the NanoCrystal® technology based on WBM approach is the most widely applied technology in the pharmaceutical industry (Goel et al., 2019). Top-down technologies usually apply physical force, such as shear force and impact force to diminish the drug particle size from micro-size to nano-size. Specific instrument such as high pressure homogenizer with sufficient pressure (normally more than 1300 bar) is essential to achieve a homogenous particle size in the obtained nanosuspension. Therefore, the design of applied top-down machine is critical for the efficiency of nanocrystal production. In generally, WBM could lead to smaller particle size compared to HPH processes according to the literature (Moschewitzer, 2013). Different instruments could reach various minimal achievable particle sizes for the same drug due to the different instrument design.

The nanocrystal preparation method could also affect the downstream formulation process, therefore, a detailed selection of the approach for production is essential. For instance, meloxicam nanosuspensions were achieved by using three different method, i.e. WBM, HPH and a combination of freeze-drying coupled with HPH. The WBM led to the smallest particle size of 88 nm as well the highest final drug release, however, tablets produced applying nanocrystals obtained from HPH and the two step approach could achieve faster dissolution rates within the first 20 min than WBM (Liu et al., 2018).

2.1.1. Special instrument design

The efficiency of particle size reduction during top-down process is highly dependent on the applied method or instrument. For the same API, different instruments can lead to various particle sizes of nanosuspensions even if it was processed under the same processes parameters, such as homogenization pressure and time, because of the different internal designs. Many studies now are attempting to improve the performance of top-down technologies based on the different principles of the top-down approach, which has widely attracted attention. In order to improve the efficiency of top-down processes or achieve special properties of nanosuspensions, many advanced and optimized technologies focus on the instrument design. Although the commercial instruments in general use the main principles mentioned in the top-down section, which means the core part of those instrument would be similar if the same mechanism was applied, some novel designed processes have been also invented and investigated recently. For example, the milling size of applied beads could affect the final particle size and smaller bead size would lead to smaller nanocrystal size. Based on this theory, it was reported that a WBM instrument allowed to use very small beads size of 50 μm (much smaller than commonly used bead size of 0.4 mm), which could significantly improve the milling efficiency, reduce the contamination and lead to sub-100 nm particle size (Li et al., 2015). Material of bead could be also substituted. In a recent study, ice beads were used as milling media, which could dissolve in water after the milling process and therefore contamination from the milling beads could be avoided (Funahashi et al., 2019).

The bottom-up technologies are generally based on mechanism of solvent-antisolvent precipitation. The API is first dissolved in a solvent and subsequently a precipitation is induced by adding the API-containing solvent phase to a non-solvent, which leads to drug nanocrystals (Liu et al., 2016). Process parameters such as solvent/antisolvent ratio, mixing type and rate, solvent as well as stabilizer selection

![Figure 1. Schematic description of modified nanocrystals by using different preparation and downstream processes for various tailor-made drug deliveries.]( figure1.png)
are critical to achieve a homogenous nanosuspension (Sinha et al., 2013). In general, the bottom-up approach required no high energy input compared to the top-down process. However, organic solvent is normally involved as the drug solvent and must be removed before the final formulation process. For bottom-up approach, the way of solvent and antisolvent mixing could affect the nanoparticle size. Most studies used a syringe containing drug dissolved in solvent, which is injected in the antisolvent (Rahim et al., 2019). Ultrasound or magnetic stirrer could also be simultaneously applied.

### Table 1. overview of examples of advanced nanocrystal preparation technologies and downstream processes.

| APIs | Particle size reduction methods | Particle size of nanosuspensions (nm) | Downstream processes | Reference |
|------|---------------------------------|---------------------------------------|----------------------|-----------|
| griseofulvin | WBM using very small beads (50 μm) | 88 | | (Li et al., 2015) |
| 4 APIs | WBM of ultra-small scale (5 mg/batch) | 200–500 | | (Li et al., 2017) |
| caffeine | WBM using organic media | 230 | | (Zhai et al., 2014) |
| 10-hydroxyamphotericin B | Prec + HPH | 131 | | (Pu et al., 2009) |
| amphotericin B | Prec + HPH | 21 | | (Sinha, 2013) |
| glibenclamide | FD + HPH | 182 | | (Salazar et al., 2011) |
| glibenclamide | FD + WBM | 199 | | (Salazar et al., 2012) |
| glibenclamide | SD + HPH | 258 | | (Salazar et al., 2013) |
| resveratrol | SD + HPH | 192 | | (Liu et al., 2016) |
| baicalin | cellulose–sodium carboxymethyl starch used as stabilizer | 846 | | (Xie et al., 2019) |
| lovastatin | alginate used as stabilizer | 370 | | (Guan et al., 2017) |
| clarithromycin | Prec + FD + HPH | 460 | | (Morakul et al., 2013) |
| curcumin | Prec with a multi-inlet vortex mixer | 20 | | (Bi et al., 2017) |
| furosemide | Buchi nano spray-dryer B-90 | 1245 | | (Li et al., 2010) |
| atovaquone | pH Based Prec | 297 | | (Kathpalia et al., 2019) |
| indomethacin | Prec using food protein as stabilizer | 100–400 | | (He et al., 2013) |
| paclitaxel | Prec using copolymer as stabilizer | 236 | | (Cao et al., 2019) |
| curcumin | Acid-base reaction method | 100 | | (Wang et al., 2017) |
| amphotericin B | Amorphous prec | 135 | | (Zu et al., 2014) |
| silymarin | Nanoporous membrane extrusion | 83 | | (Guo et al., 2013) |
| resveratrol | HPH | 559–625 | Nanocrystals was loaded in microparticle by SD for inhalation. | (Liu et al., 2019) |
| cholecalciferol | Prec | 302 | Nanocrystals was loaded in microneedle for transdermal. | (Abdelghany et al., 2019) |
| Curcumin | Prec | ca.400-1000 | Encapsulated nanocrystals in micronneedle for transdermal. | (Staedtke et al., 2010) |
| amphotericin B | FD + HPH | 65 | Encapsulated nanocrystals in human erythrocytes to prevent the drug’s toxicity on the phagocytosing cells. | (Colombo et al., 2017) |
| dexamethasone | WBM | 272 | FD was used to dry and reduce the drug crystallinity. | (Qiao et al., 2017) |
| andrographolide | WBM | 244 | Amorphization was found after FD processes. Improved bioavailability was observed. | (Nguyen et al., 2017) |
| darunavir | WBM | 295 | Coaxial electrospaying was used to encapsulate nanocrystals within polymer shell. | (Kayaert et al., 2011) |
| naproxen | WBM | 370 | Fluidized bed pellet coater achieved the drug release within 5 min. | (Parmentier et al., 2017) |
| itraconazole | WBM | <200 | Fluid bed coating was used to coat nanosuspensions onto beads. The fastest dissolution rate was from small sugar beads size, HPMC VLV as film polymer and lowest layering level. | (Ye et al., 2016) |
| efavirenz | HPH | 320 | Drug nanosuspension was mixed with polymer using a twin-screw extruder to get nanocrystal solid dispersions. | (Ye et al., 2016) |
| clotrimazole | Pre | / | hot melt extruder coupled with polymer matrix was used to dry amorphous nanosuspension. | (Gajera et al., 2018) |
| folic acid | HPH | 407 | Nanosuspension was used as printing ink and was printed on edible paper carriers. An example of personalized medicine. | (Pardeike et al., 2011) |
| paclitaxel | anti-solvent method | 380 | Fluorescent dyes were combined with nanocrystals for in vivo disease imaging. | (Hollis et al., 2014) |
| quercetin | HPH | 753 | Drug nanocrystals were loaded into fast dissolving maltodextrins films, which showed faster dissolution rate than the freeze-dried nanocrystals. | (Lai et al., 2015) |

WBM: wet bead milling; Prec: precipitation; FD: freeze-drying; SD: spray-drying; HPH: high pressure homogenization.
applied in order to get a homogenous size distribution. One improved method was capable of mixing the solvent and antisolvent inside the high pressure homogenizer, which could result in much smaller size compared to normal precipitation operation (Sinha et al., 2013). The precipitation with a multi-inlet vortex mixer is another modified bottom-up process, which allows the API solvent and anti-solvent to enter a special designed mixer in different directions. This method could effectively control the particle growth with the aid of stabilizer and the particle size of obtained

Figure 2. Correlation between particle morphologies and their particle sizes after 20 homogenization cycles at 1500 bar of 5 APIs (LD: laser diffraction; PCS: photon correlation spectroscopy; SD: spray drying; SC: sodium cholate). Modified after reference (Liu et al., 2018).
nanosuspensions was smaller than 100 nm. For example, a very small particle size (20 nm) of curcumin was achieved by using this technology. This study also confirmed that the 20 nm curcumin nanosuspensions showed comparable biodistribution to curcumin solution in most tissues during animal experiment (Bi et al., 2017).

Besides top-down and bottom-up technologies, some novel approaches such as acid-base reaction based method were also invented. Drug nanosuspensions can be achieved by using the rapid generated CO$_2$ bubbles during the acid-base reaction. For example, curcumin, stabilizer and acid were dissolved in organic solvent and then it was dried by using rotary evaporation to obtain an acid-phase. The carbonate solution was finally added in the acid-phase to achieve curcumin nanosuspension. Particle sizes of around 100 nm could be produced by using different stabilizers and 6 h’ stability was also confirmed (Wang et al., 2017). Like top-down approach, this method uses the external energy (from chemical reaction) to reduce the drug particle size, but it doesn’t need any special energy input equipment. Normally, the selected solvent used for bottom-up process is organic solvent and antisolvent is water. However, the change of pH resulting in the solubility alteration could also be applied as a novel bottom-up method (Li et al., 2018). Atovaquone nanosuspension was reported to be prepared by using this concept and it could have a long stability within 6 months (Kathpalia et al., 2019).

2.1.2. Physical modification of drug before top-down

In addition, physical properties of drug could finally determine the smallest particle size obtained, which means there is always a limitation no matter which kind of instrument is used. For example, it is normally difficult for a lot of APIs to get a particle size smaller than 100 nm by using HPH technologies (Moschwitzter, 2013). Therefore, some advanced technologies have been trying to apply modified drug with improved physical properties for top-down process.

Drug physical properties have significant influence on the particle size reduction effectiveness (Liu et al., 2015, 2018) and the consequent dissolution rate. The unmodified APIs from the synthesis employed for the top-down process can be firstly treated by different modification procedures, e.g. precipitation (Sinha et al., 2013; Singh et al., 2018; Homayouni et al., 2019), spray-drying (Salazar et al., 2013; Liu et al., 2016), freeze-drying (Salazar et al., 2012), high speed homogenization (Oktay et al., 2019) or WBM (Bartos et al., 2018). These modification processes combining with subsequent top-down steps are commonly referred to as combination processes. For example, resveratrol and sodium cholate was firstly dissolved in ethanol and processed by spray-drying. The spray-dried resveratrol powder could highly improve the followed HPH efficiency and only 5 homogenization cycles were enough to obtain the smallest particle size of 195 nm. Conversely, the standard HPH using raw resveratrol could only lead to a particle size of 569 nm after 20 cycles (Liu et al., 2016).

The direction to modify API has not been answered by published studies to date. Based on the limited research, the mechanism to obtain drug with improved milliability is still unclear and needs further systematical investigation (Liu et al., 2015).

Physical properties, such as solid state, particle morphology, particle size, crystallite size and Young’s modulus, have been studied of the correlation about milliability. Table 2 gives a summary of physical properties that may influence the top-down production. For example, some related literature has proved that the modification of drug physical properties such as particle morphology (George & Ghosh, 2013; Liu et al., 2016) might have direct correlation to the particle size reduction efficiency and the minimal achievable particle size. In one recent study, five different kinds of APIs were modified (i.e. spray-dried) under the same experimental conditions. A porous structure or reduced crystallite size observed from the SEM was speculated to have direct correlation with the HPH efficiency, because the only one API, i.e. hesperetin, without any change of particle morphology after direct spray-drying process, was not shown contribution to the followed top-down process (Figure 2) (Liu et al., 2018). In addition, the solid state (Salazar et al., 2011; Liu et al., 2018), polymorphism (Sharma et al., 2011) and Young’s modulus (Cerdeira et al., 2011) of certain APIs were also found possible effect on the top-down processes, among which solid state was attracted a lot of attentions recently.

Amorphous state or reduced crystallinity obtained from such as spray-drying or freeze-drying means the irregular molecular arrangement compared to the crystal state, which could also be used for HPH or WBM processes (Kuroiwa et al., 2018). For crystal API, the breakage points of the powder during top-down processes happened at boundaries of the crystallite (Knieke et al., 2009), but amorphous drug due to the modified molecular arrangement might theoretically reflect different behaviors of particle size reduction when it was exposed to external forces. Glibenclamide nanosuspensions was produced and systematically investigated by using freeze-dried API with various reduced crystallinities in the method of design of experiment (DoE). The optimized particle size distribution was obtained from amorphous freeze-dried powder with porous morphology after HPH process (Salazar et al., 2011). In another study, resveratrol was modified by using three different methods (spray-drying, rotary evaporation and quench-cooling) and was further nanosized by HPH. Interestingly, the smallest particle size of nanosuspension was produced from the spray-dried sample without significantly reduced crystallinity compared to the amorphous sample obtained after rotary evaporation (Liu et al., 2018). Although solid state could play a part according to the published literature, the selection of modification approach seemed also important in order to produce the optimized powder for followed top-down process.

| Table 2. possible factors influencing efficiency of particle size reduction. |
|-----------------|-----------------|
| API property    | Reference        |
| particle size/ crystallite size | (Liu et al., 2018) |
| polymorphism    | (Sharma et al., 2011) |
| particle morphology | (Liu et al., 2016, 2018, 2018) |
| solid state     | (Salazar et al., 2011, 2013; Liu et al., 2018) |
| Young’s modulus | (Cerdeira et al., 2011) |
2.2. Ultra-small scale for initial research stage

Ultra-small production scale means further minimized drug load requirement for production compared to normal lab scale. Reduction of drug amount, especially for WBM, is valuable for API at initial research stage when the available quantity is limited or the drug is very expensive. For the lab scale WBM, a magnetic stirrer coupled with beaker or glass bottle containing beads could be used as a substitute for simulating of milling instrument. In one study about ultra-small scale production, the milling drug weight per batch can be minimized to only 5 mg by using a 1 ml milling chamber coupled with a shaker, which could be used to select stabilizer in a time as well as material saving manner. The obtained particle sizes of nanosuspension were proven to be comparable to those produced from standard lab scale experiments (Liu et al., 2017). Similar studies were also found in some recent literature (Romero et al., 2016; Hagedorn et al., 2019).

2.3. Reduced crystallinity of drug nanocrystals for improved bioavailability

2.3.1. Reduced crystallinity of drug nanocrystals by using bottom-up

Amorphous or reduced crystallite nanosuspension can also be achieved by using some modified bottom-up approaches. The bioavailability of this kind of pure drug nanoparticle is often improved because of both its reduced particle size and low crystallinity. Nano-amorphous drug could possess better in vitro and in vivo performances than the nanocrystals as well as micro-sized amorphous formulations (Gajera et al., 2019). By itself, top-down methods do not lead to reduced the crystallinity of API due to the existence of water ($T_g$, $-130 ^\circ C$) (Sharma et al., 2009). Bottom-up methods are the most reported approaches to produce amorphous nanosuspension (Jog & Burgess, 2017). In order to keep the amorphous state, the preparation process must be accurately controlled to avoid recrystallization and particle growth (Lindfors et al., 2007).

For example, amorphous amphotericin B nanoparticles were achieved by using precipitation. Process parameters, such as stabilizer concentration, temperature, stirring speed and time, and drug concentration were investigated and optimized to obtain the amorphous amphotericin B nanoparticles with a particle size of 135 nm (Zu et al., 2014). Besides the classic precipitation process, recently some special designed bottom-up methods were also used to produce amorphous nanosuspensions. Nanoporous membrane extrusion (NME) method is a technology, which pumped drug in solvent phase through a nanoporous membrane into the receiver solution. A particle size of 100 nm amorphous nanosuspensions could be obtained in the receiver solution. The nanoporous membrane played an important part in particle size reduction process and also avoided the aggregation (Guo et al., 2013).

2.3.2. Reduced crystallinity of drug nanocrystals by using downstream

In general, solidification processes such as spray-drying or freeze-drying would not change the solid state of drug nanosuspension. However, recent studies found that drug solid state of nanosuspension could also be modified during the downstream processes. Freeze-drying is a technology, which can be used to gently dry drug nanosuspensions, preserve the particle size and improve the physical and chemical stability at the same time. Recently, it was also reported that this technology could be also employed to reduce the crystallinity of dexamethasone and tacrolimus nanosuspensions. It was proven that the obtained saturation solubility could be affected by both particle size and the crystallinity in this study (Colombo et al., 2017).

On the other side, special attention should be paid to the approach of correctly measuring the solid state of nanosuspension. One study in our research group revealed that DSC as a commonly used solid state technology was not suitable for characterization of dried nanosuspension when the API had a solubility in coexisting stabilizer, which might be concluded an inconsistent result with PXRD or other measurements (Liu et al., 2018).

The hot-melt extrusion is another way to process the obtained nanosuspensions. For example, the poorly soluble drug, efavirenz, was first prepared by HPH to achieve drug nanosuspension, which was then mixed with polymer Soluplus® using a twin-screw extruder to get nanocrystal solid dispersions. 6 months’ stability was confirmed. The increased dissolution rate was achieved using this methods resulted not only from the reduced particle size but also from the improved wettability due to the intimate polymer contact (Ye et al., 2016). In another study, hot melt extruder coupled with polymer matrix were used to dry amorphous nanosuspension obtained from bottom-up approach. The solubility improvement afterwards could be attributed to the nanosized API as well as the applied polymer matrix (Gajera et al., 2018).
2.4. Nanocrystals loaded in carrier (or carrier-free) for controlled drug release and targeting

2.4.1. Carrier-free (stabilizer-based) nanocrystals
Stabilizer could not only affect the stability of obtained nanosuspension but also the efficiency of particle size reduction as well as in vivo and in vitro performances. The commonly used stabilizer could be mainly divided into two types, i.e. ionic surfactants (sodium cholate, sodium dodecyl sulfate and so on) and polymer (hydroxypropyl methylcellulose, polyvinyl alcohol and so on), which are all basically pharmaceutical excipients and can be used individually or in combination. Electrostatic repulsion or steric barrier for the two kinds of stabilize are the reason that could prevent the aggregation of nanocrystals, respectively (Yang et al., 2018). Figure 3 gives a schematic description of the two different mechanisms. In addition, the selected stabilizer could also have influence on the bioavailability and a recent study in 2019 found that combination of ionic surfactant and polymer could highly contribute to the bioavailability (Wang et al., 2019). Some stabilizers such as TPGS and poloxamers are P-gp inhibitors and could reverse the drug resistance (Tuomela et al., 2016). For example, Paclitaxel nanosuspension with TPGS significantly prevented the drug resistant of P-gp for H460 human cancer cells and was observed five times higher tumor inhibition than the paclitaxel solution (Gao et al., 2014). Tween 80 as the nanosuspension stabilizer could contribute to the transportation of curcumin to brain in the way of receptor-mediated endocytosis (Dibaei et al., 2019). In a recent study, the charges of stabilizers were proven the effect on the mucoadhesive properties and permeation of cell monolayers, which confirmed that positively charged nanosized clarithromycin was observed better mucoadhesive than the not charged and the negatively charged nanocrystals, and both charged nanocrystals reflected an improved drug delivery compared to the uncharged (Soisuwon et al., 2019). In another study, muco-inert Pluronic F127 as the stabilizer for budesonide nanosuspension was proven to lead to highly decreased number of inflammatory macrophages compared to the microsized budesonide, when model mouse were given enema (Date et al., 2018). In addition, molecular weights of the applied polymer could also affect the in vivo oral absorption. It was found that the fenofibrate nanocrystals stabilized by low molecular weight hypromellose (HPMC) could transport the mucin faster than the large one and therefore possessed optimized oral absorption (Ueda et al., 2019).

Novel stabilization strategies are usually developed aiming to find the substitution for the above mentioned stabilizer and possess improved stability or specific function. For example, baicalin nanocrystals were homogenized by using a surfactant free method, which applied a combination of nanocrystalline cellulose and sodium carboxymethyl starch as co-stabilizer. In vitro dissolution and in vivo bioavailability were both observed superior compared to the raw API and the redispersibility was also benefited after the spray-drying process (Xie et al., 2019). In another study, alginate was used as stabilizer for HPH, which was an anionic polysaccharide and possessed both electrostatic and steric effects. The main advantage of this stabilizer was the low application amount in nanosuspension, which was only 0.5–1% (w/w) of the API (Guan et al., 2017).

Same as the stabilizer used for top-down process, the stabilizer within the bottom-up processes can also not only affect the stability of obtained nanosuspensions but also the production efficiency and in vitro as well as in vivo performance. Besides widely used pharmaceutical stabilizer such as HPMC, PVP, sodium cholate and Tween 80, some novel stabilizer, e.g. food protein (soybean protein) was attempted, which showed improved stabilization efficiency compared to traditional stabilizers. The obtained nanosuspensions could be further freeze-dried and showed good redispersibility (He et al., 2013). In another study, a biocompatible amphiphilic block copolymer poly (L-phenylalanine)-b-poly(L-aspartic acid) was used as the stabilizer for a combination of precipitation and HPH process to produce paclitaxel nanosuspension, which was then proven to significantly decrease the plasma peak concentration and prolong plasma circulating time. In addition, this stabilizer could contribute to the drug penetration of multidrug resistance cells (Cao et al., 2019).

Stabilizer as one of the most important parts of nanosuspension for both top-down and bottom-up methods (Zhou et al., 2018), it was found that more and more naturally occurring materials from plants or animals are used as the novel because of their good biocompatibility according to the recent studies. In addition, modified chemical surfactants or polymers by using organic synthesis are another large group of advanced stabilizers that could achieve improved stability or controlled release.

2.4.2. Nanocrystals loaded in carrier
Drug nanosuspensions can be further converted to not only tablets (Mori et al., 2016; Anup et al., 2018), capsules (Bonhoeffer et al., 2018), creams (Lai et al., 2015), injectables (Lu et al., 2016; Yang et al., 2017; Sigfriðsson et al., 2019) or other traditional formulations (Pailla et al., 2019), but it can be also loaded in carrier such as human erythrocytes (Staedtke et al., 2010) or be combined with fluorescent dyes (Zhao et al., 2011) with the development of modern pharmaceutical technologies. This review would mainly focus on recently developed novel approaches because the traditional methods have been summarized in many related literature (Van Eerdenbrugh et al., 2008; Malamataris et al., 2016).

Although drug nanocrystals is a carrier free system, it usually needs an approach or medium for the drug delivery. Drug nanocrystals can be further loaded in novel carriers, which sometimes can significantly alter their physical properties and subsequently lead to modified release (Wei et al., 2018). Many recently related publication showed that loading nanocrystals in different new carriers is an attractive research direction. Besides traditional tablet or capsule, novel carriers can also be cell or specific designed material, such as gel or film. Examples are listed as follows.

2.4.2.1. Nanocrystals loaded in carriers for oral
Nanocrystals can be loaded in oral dosage such as common tablet or capsule. There are different ways to handle the
obtained nanosuspensions. Normally, drug nanosuspension could be dried by using freeze-drying (Alshweiat et al., 2018) or spray-drying (Nair et al., 2019) to produce powder, which then is applied for tabletting or other oral formulation. Alternatively, nanosuspension could be also directly used as an ingredient of formulation for downstream process. For example, nanosuspension could be used as wet agent to mix with other excipients such as starch for granulation and then was applied for tabletting (Liu et al., 2018). In one study, glyburide nanocrystals were loaded in lactose monohydrate and microcrystalline cellulose for tabletting, which was finally observed highly improved in vivo AUC value compared to the marketed tablets (Ali et al., 2019).

Recently, fluidized bed can also be used to dry drug nanosuspensions and simultaneously coat them onto sugar spheres. These layered cores can be further coated with functional polymers for to achieving e.g. controlled drug release properties. For example, naproxen and cinnarizine nanosuspensions were processed by a fluidized bed pellet coater. Both showed improved dissolution compared to their raw APIs. In this study, it was confirmed that drug physicochemical properties have important effect on dissolution behavior after laying processes, which could not be predicted from the information of nanosuspensions (Kayaert et al., 2011).

In addition, drug nanocrystals could be incorporated into oral carrier such as fast dissolving films. Lai et al. applied HPH to prepare quercetin nanosuspensions and then a casting method was used to prepare the film (maltodextrins as film forming material). This downstream method could effectively avoid the physical stability issue related to nanoparticles systems. Interestingly, the nanocrystal loaded films showed much faster dissolution rate compared to the freeze-dried nanocrystals (Lai et al., 2015).

2.4.2.2. Nanocrystals loaded in carriers for inhalation.
Nanocrystals are homogenous small drug particles, which are suitable to be loaded in microparticle by using instrument such as spray-drying for inhalation and improve the corresponding bioavailability as well as the adhesion of the poorly soluble drug owing to the enlarged drug particle surface. The microparticle as a carrier for nanocrystals might be consisted ofmannitol or other pharmaceutical excipient. Most of the inhalation related nanocrystal products were designed for immediate functions, however, recent studies found that nanocrystals loaded in polymer such as hyaluronic acid could lead to continuous drug release and improved bioavailability after administration. The polymer or carrier used could prevent mucociliary clearance and consequently resulted in extended drug retention, where a shrinking of the dissolution rate was not essential (Liu et al., 2018).

In another study, it was found that the stabilizer used for HPH could significantly affect the in vivo pharmacokinetic performance. For example, one study achieved resveratrol nanocrystals loaded in mannitol based microparticles for inhalation and positively charged surfactant chitosan contributed to the drug retention and maximum avoided the API entrance of the general circulation (Liu et al., 2019).

2.4.2.3. Nanocrystals loaded in carriers for transdermal.
Drug nanocrystals could be loaded in commonly used such as gel ( Barkat et al., 2017; Kumar et al., 2019) to achieve transdermal administration, which could lead to improved in vitro and in vivo performances compared to the microsized API formulation or drug solution (Oktay et al., 2018). For example, silver sulfadiazine nanosuspension was produced by HPH to obtain an average particle size of 369 nm and then it was loaded in thermosensitive hydrogel. The drug release results showed obvious improvement of the loaded sample compared to the commercial product and the in vitro antibacterial experiment also was found superior for the nano-silver sulfadiazine formulation (Liu et al., 2018). Some combinations of nanocrystals with specified designed carriers have been reported.

Microneedle is an advanced and painless drug delivery technology, which has been recently combined with nanosuspension (Vora et al., 2018; Permana et al., 2019). Rapidly dissolving microneedles, which could be fully dissolved and degraded in the skin (Sullivan et al., 2008), is difficult for poorly water soluble compound to be applied due to the distribution problem. Therefore, nanosuspension as a homogenous system can used to remedy this defect. On the other side, the poor permeation ability of nanosuspension for stratum corneum could be dissolved by combined with microneedles. Abdelghany et al applied curcumin as model compound and the obtained nanocrystals loaded microneedles could reach 500 μm in neonatal porcine skin and dissolved within 60 min, afterwards, lead to a depth of 2300 μm, which was more notable than the simple curcumin nanosuspension (Abdelghany et al., 2019). In addition, a long term acting rilpivirine nanosuspension in microarray patches was achieved and investigated, which showed that the API plasma concentration in rats was about 10 times higher than former researches. Moreover, rilpivirine could be found in lymph nodes, which means this antiretroviral API could be transported to one important site of HIV duplication during prolonged duration (McCruden et al., 2018).

2.4.2.4. Nanocrystals loaded in cell for targeting. Human cells, unlike synthetic chemical carrier, are considered as biocompatible and have been applied for the drug carriers (Tan et al., 2015). Cells, such as red blood cells, leukocytes or stem cells have been reported to be used as carriers for nanoparticle to get required drug target (Pang et al., 2017). However, nanocrystals generally possessed larger particle size range of 100–1000 nm than other nanoparticle systems (normally smaller than 100 nm). Therefore, it is essential to produce a smaller particle size in order to combine with cell carriers. For example, amphotericin B is a drug with poor solubility, low in vivo stability and high toxicity. In order to overcome those problems, amphotericin B nanocrystals were firstly prepared by the H 96 technology (FD combined by HPH). A smaller particle size (i.e. 65 nm) was obtained than one-step HPH process. The achieved nanocrystals were then encapsulated in human erythrocytes by applying hypotonic hemolysis, where finally could effectively prevent the drug’s toxicity on the phagocytosing cells (Staedtke et al., 2010).
2.5. Printing nanosuspension for personalized medicines

Pharmaceutical printing technology was developed aiming personalized medicines to meet the need of patient individual dosing options, which possesses advantages such as accurate control of drug content and convenience of application. The number of publication regarding as has increased significantly recently, which indicates the rising popularity of this technology. Normally, solution (organic or water based) containing API is used for the printing process (Alomari et al., 2015). In one study, 10% (w/w) folic acid nanosuspension as printing ink could be printed on edible paper carriers via inkjet-type printing technique. This study confirmed that particle size of drug nanocrystals is small enough to be used as ink without clogging. The obtained product had advantages of both improved dissolution rate as well as the characters of personalized medicines (Pardeike et al., 2011).

2.6. Hybrid nanocrystals for drug tracking

Drug nanocrystals tracking in vivo is difficult because of the ongoing dissolution and limited usable method for detection. Hybrid nanocrystals are the combination of API and fluorescent dyes (Lu et al., 2017, 2019; Mohammad et al., 2019), which was invented to track nanocrystals after administration. It can be achieved by using bottom-up methods. Firstly, dyes, such as fluorescein and rhodamine B were dissolved in water as antisolvent and then it was mixed by the drug solution. Hybrid drug nanocrystals possess fluorescence because of the attached dyes (Zhao et al., 2011). This technology was designed for in vivo disease imaging, such as the drug distribution during cancer treatment (Hollis et al., 2014). For example, curcumin was hybridized with fluorescent dyes from crystal lattices, which was injected intravenously. Because of the coupled fluorescent dyes, it could be shown that most API was cleared from blood very fast and accumulate predominately in liver and lung (Wang et al., 2018). In another study, an anti-HIV drug 5-Chloro-3-phenylsulfonylindole-2-carboxamide was coupled with fluorescent dyes to formulate hybrid nanocrystals for vaginal delivery and it could be imaged by confocal microscopy that nanocrystals stayed on the surface of the cell membranes at the beginning and then transported into the cytoplasm (Gong et al., 2019).

In addition, poorly water soluble dyes, such as Nile red could also be directly nanosized by WBM, which could be applied to study the nanocrystal penetration and accumulation in the hair follicles with the assistance of fluorescence imaging as well as microscopy technology (Corrias et al., 2017).

4. Conclusion

Drug nanocrystals is simple but effective drug delivery approach for improvement of bioavailability for poorly soluble APIs. The developing trend regarding as is changing to modification of the pure drug nanocrystals by applying various novel preparation or downstream processes for specific required drug delivery approaches according to most recent studies. These modifications take advantage of the simple composition of drug nanosuspension and also endue it with improved or modified properties, such as controlled release, in vivo disease tracing or targeting. Some of them demonstrated more advantages compared to traditional pure nanocrystals. However, high cost and complicated process operation are still the main hurdles for a broader application of some of the new technologies. The development of the pharmaceutical technologies and increased various requirements from the clinical would lead to the appearance of more practical tailor-made nanocrystals.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

Tao Liu would like to thank A Project of Shandong Province Higher Educational Science and Technology Program [project no. J18KA269], Shandong Provincial Key R&D Program [project no. 2019GSF107006] and Qingdao Source Innovation Program [project no. 19-6-2-38-cg] for the financial supports.

References

Abdelghany S, Tekko IA, Vora L, et al. (2019). Nanosuspension-based dissolving microneedle arrays for intradermal delivery of curcumin. Pharmaceutics 11:E308
Ali HSM, Hanafy AF, Alqurshi A. (2019). Engineering of solidified glyburide nanocrystals for tablet formulation via loading of carriers: downstream processing, characterization, and bioavailability. Int J Nanomed 14:1893–906.
Alomari M, Mohamed FH, Basit AW, Gaisford S. (2015). Personalised dosing: printing a dose of one’s own medicine. Int J Pharmaceut 494:569–77.
Alshewiet A, Katona G, Csoka I, Ambrus R. (2018). Design and characterization of loratadine nanosuspension prepared by ultrasonic-assisted precipitation. Eur J Pharm Sci 122:94–104.
Anup N, Thakkar S, Misra M. (2018). Formulation of olanzapine nanosuspension based orally disintegrating tablets (ODT); comparative evaluation of lyophilization and electrospaying process as solidification techniques. Adv Powder Technol 29:1913–24.
B. Sinha. (2013). Systematical investigation of the cavi-precipitation process to prepare drug nanocrystals. Berlin: Free University of Berlin.
Bartos C, Jojart-Laczkovich O, Katona G, et al. (2018). Optimization of a combined wet milling process in order to produce poly(vinyl alcohol) stabilized nanosuspension. DDDT 12:1567–80.
Bi C, Miao XQ, Chow SF, et al. (2017). Particle size effect of curcumin nanosuspensions on cytotoxicity, cellular internalization, in vivo pharmacokinetics and biodistribution. Nanomed-Nanotechnol 13:943–53.
Bonhoeffer B, Kwade A, Juhinke M. (2018). Alternative manufacturing concepts for solid oral dosage forms from drug nanosuspensions using fluid dispensing and forced drying technology. J Pharm Sci 107:909–21.
Cao YP, Wei ZH, Li MM, et al. (2019). Formulation, pharmacokinetic evaluation and cytotoxicity of an enhanced-penetration paclitaxel nanosuspension. CCĐT 19:338–47.
Cerdeira AM, Mazzotti M, Gander B. (2011). Role of milling parameters and particle stabilization on nanogrinding of drug substances of similar mechanical properties. Chem Eng Technol 34:1427–38.
Colombo M, Orthmann S, Bellini M, et al. (2017). Influence of drug brittleness, nanomilling time, and freeze-drying on the crystallinity of poorly water-soluble drugs and its implications for solubility enhancement. AAPS PharmSciTech 18:2437.

Corrias F, Schlich M, Sinico C, et al. (2017). Nile red nanosuspensions as investigative model to study the follicular targeting of drug nanocrystals. Int J Pharm 524:1–8.

Couillaud BM, Espeau P, Mignet N, Corvis Y. (2019). State of the art of pharmaceutical solid forms: from crystal property issues to nanocrystals formulation. ChemMedChem 14:8–23.

Date AA, Halpert G, Babu T, et al. (2018). Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease. Biomaterials 185:97–105.

Dibaei M, Rouni MR, Sheikholeslami B, et al. (2019). The effect of surface treatment on the brain delivery of curcumin nanosuspension: in vitro and in vivo studies. JN 14:5477–90.

Fontana F, Figueiredo P, Zhang P, et al. (2018). Production of pure drug nanocrystals and nano co-crystals by confinement methods. Adv Drug Deliv Rev 131:3–21.

Funahashi I, Kondo K, Ito Y, et al. (2019). Novel contamination-free wet milling technique using ice beads for poorly water-soluble compounds. Int J Pharm 563:413–25.

Gajera BY, Shah DA, Dave RH. (2018). Investigating a novel hot melt extrusion-based drying technique to solidify an amorphous nanosuspension using design of experiment methodology. AAPS PharmSciTech 19:3778–90.

Gajera BY, Shah DA, Dave RH. (2019). Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology. Int J Pharmaceut 559:348–59.

Gao L, Liu GY, Ma JL, et al. (2014). Paclitaxel nanosuspension coated with P-gp inhibitory surfactants: II. Ability to reverse the drug-resistance of H460 human lung cancer cells. Colloid Surface B 117:122–7.

George M, Ghosh I. (2013). Identifying the correlation between drug/stabilizer properties and critical quality attributes (CQAs) of nanosuspension formulation prepared by wet media milling technology. Eur J Pharm Sci 48:142–52.

Giglioibianco MR, Casadidio C, Censi R, Martin PD. (2018). Nanocrystals of poorly soluble drugs: drug bioavailability and physicochemical stability. Pharmaceutics 10:E134

Goel S, Sachdeva M, Agarwal V. (2019). Nanosuspension technology: recent patents on drug delivery and their characterizations. DDF 13: 91–104.

Gong T, Patel SK, Parniak MA, et al. (2019). Nanocrystal formulation improves vaginal delivery of CSIC for HIV prevention. AAPS PharmSciTech 20:286.

Guo P, Liu FY, Li Y, et al. (2017). Exploration of alginate as potential stabilizers of nanosuspension. AAPS PharmSciTech 18:3172–81.

Gupta J, Zhang YL, Liu QY, et al. (2017). Exploration of alginates as potential stabilizers of nanosuspension. AAPS PharmSciTech 18:3172–81.

Homayouni A, Amini M, Sohrabi M, et al. (2019). Curcumin nanoparticles containing poloxamer or soluplus tailored by high pressure homogenization using anisotropic crystallization. Int J Pharm 562:124–34.

Jacko SV, Brough C, Williams RO. 3rd, (2018). Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery - An update. Int J Pharm 535:379–92.

Jog R, Burgess DJ. (2017). Pharmaceutical amorphous nanoparticles. J Pharm Sci 106:39–65.

Kathpalia H, Juvekar S, Shidhaye S. (2019). Design and in vitro evaluation of atovaquone nanosuspension prepared by pH based and anti-solvent based precipitation method. Colloid Interfac Sci 29:26–32.

Kayaert P, Anne M, Van den Moeter G. (2011). Bead layering as a process to stabilize nanosuspensions: influence of drug hydrophobicity on nanocrystal reagglomeration following in-vitro release from sugar beads. J Pharm Pharmocol 63:1446–53.

Knieke C, Sommer M, Peukert W. (2009). Identifying the apparent and true grinding limit. Powder Technol 195:25–30.

Kumar M, Shanthi N, Mahato AK, et al. (2019). Preparation of lufucarnozole nanocrystals loaded hydrogel for improvement of dissolution and antifungal activity. Heliyon 5:e01688.

Kuroiwa Y, Higashi K, Ueda K, et al. (2018). Nano-scale and molecular-level understanding of wet-milled indomethacin/poloxamer 407 nanosuspension with TEM, suspended-state NMR, and Raman measurements. Int J Pharm 537:30–9.

Lai F, Franceschini I, Corrias F, et al. (2015). Maltodextrin fast dissolving films for quercetin nanocrystal delivery. A feasibility study. Carbohydr Polym 121:217–23.

Lai F, Schlich M, Pireddu R, et al. (2015). Production of nanosuspensions as a tool to improve drug bioavailability: focus on topical delivery. CPD 21:6089–103.

Li M, Yaragudi N, Aflabi A, et al. (2015). Sub-100 nm drug particle suspensions prepared via wet milling with low bead contamination through novel process intensification. Chem Eng Sci 130:207–20.

Li Q, Chen F, Liu Y, et al. (2018). A novel albumin wrapped nanosuspension of meloxicam to improve inflammation-targeting effects. JN 13:9711–25.

Li YA, Antón N, Arpagaus C, et al. (2010). Nanoparticles by spray drying using innovative new technology: the Buchi Nano spray dryer B-90. J Control Release 147:304–10.

Lindfors L, Skantze P, Skantzze U, et al. (2007). Amorphous drug nanosuspensions. 3. Particle dissolution and crystal growth. Langmuir 23: 9866–74.

Liu M, Hong C, Li G, et al. (2016). The generation of myricetin-nicotinamide nanocrystals by top down and bottom up technologies. Nanotechnology 27:395601.

Liu Q, Guan J, Sun Z, et al. (2019). Influence of stabilizer type and concentration on the lung deposition and retention of resveratrol nanosuspension-in-microparticles. Int J Pharm 569:118562.

Liu T, Han M, Tian F, et al. (2018). Budesonide nanocrystal-loaded hyaluronic acid microparticles for inhalation: in vitro and in vivo evaluation. Carbohydr Polym 181:1143–52.

Liu T, Muller RH, Moschitzper JP. (2015). Effect of drug physico-chemical properties on the efficiency of top-down process and characterization of nanosuspension. Expert Opin Drug Del 12:1741–54.

Liu T, Muller RH, Moschitzper JP. (2016). Systematical investigation of a combinative particle size reduction technology for production of resveratrol nanosuspensions. AAPS PharmSciTech 18:1683–91.

Liu T, Muller RH, Moschitzper JP. (2018). Consideration of the solid state for resveratrol nanocrystal production. Powder Technol 332:63–9.

Liu T, Muller RH, Moschitzper JP. (2018). Production of drug nanosuspensions: effect of drug physical properties on nanosizing efficiency. Drug Dev Ind Pharm 44:233–42.

Liu T, Yao G, Zhang X, et al. (2018). Systematical investigation of different drug nanocrystal technologies to produce fast dissolving meloxicam tablets. AAPS PharmSciTech 19:783–91.

Liu T, Yao GL, Liu XT, Yin HP. (2017). Preparation of meloxicam to improve inflammation-targeting effects. IJN 13:9711–25.

Lu Y, Li Y, Wu W. (2016). Injected nanocrystals for targeted drug delivery. Acta Pharm Sin B 6:106–13.

Lu Y, Ly L, Yi T. (2019). Hybrid drug nanocrystals. Adv Drug Deliv Rev 143:115.

Lu Y, Qi JP, Dong XC, et al. (2017). The in vivo fate of nanocrystals. Drug Discov Today 22:744–50.
Barkat MA, Harshita , Ahmad I, et al. (2017). Nanosuspension-based Aloe vera gel of silver sulfadiazine with improved wound healing activity. AAPS PharmSciTech 18:3274–85.

Malamatari M, Somavarapu S, Taylor KMG, Buckton G. (2016). Solidification of nanosuspensions for the production of solid oral dosage forms and inhalable dry powders. Expert Opin Drug Del 13: 435–50.

Malamatari M, Taylor KMG, Malamataris S, et al. (2018). Pharmaceutical nanocrystals: production by wet milling and applications. Drug Discovery Today 23:534–47.

McCrudden MTC, Larraneta E, Clark A, et al. (2018). Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting ripivirine nanosuspension. J Control Release 292:119–29.

Miao XQ, Yang WW, Feng T, et al. (2018). Drug nanocrystals for cancer therapy. Wires Nanom Nanobi 10x1499.

Mohammad IS, Hu H, Yin L, He W. (2019). Drug nanocrystals: fabrication methods and promising therapeutic applications. Int J Pharm 562: 187–202.

Morakul B, Sukrsriworapong J, Leanpolchareanchai J, Junyaprasert VB. (2013). Precipitation-lyoophilization-homogenization (PLH) for preparation of clarithromycin nanocrystals: influencing factors on physicochemical properties and stability. Int J Pharmaceut 457:187–96.

Mori D, Makwana J, Parmar R, et al. (2016). Formulation, evaluation and optimization of the felodipine nanosuspension to be used for direct compression to tablet for in vitro dissolution enhancement. Pak J Pharm Sci 29:1927–36.

Moschwitzer JP. (2013). Drug nanocrystals in the commercial pharmaceutical development process. Int J Pharm 453:142–56.

Muller RH, Keck CM. (2012). Twenty years of drug nanocrystals: where are we, and where do we go? Eur J Pharm Biopharm 80:1–3.

Nair A, Khunt D, Misra M. (2019). Application of quality by design for optimization of spray drying process used in drying of Risperidone nanosuspension. Powder Technol 342:156–65.

Nguyen DN, Clasen C, Van den Mooter G. (2017). Encapsulating darunavir nanocrystals within Eudragit L100 using coaxial electrospaying. Eur J Pharm Biopharm 113:50–9.

Oktay AN, Ilbasmis-Tamer S, Celebi N. (2019). The effect of critical process parameters of the high pressure homogenization technique on the critical quality attributes of flurbiprofen nanosuspensions. Pharm Dev Technol 1–28.

Oktay AN, Karakucuk A, Ilbasmis-Tamer S, Celebi N. (2018). Dermal flurbiprofen nanosuspensions: optimization with design of experiment approach and in vitro evaluation. Eur J Pharm Sci 122:254–63.

Pang L, Zhang C, Qin J, et al. (2017). A novel strategy to achieve effective drug delivery: exploit cells as carrier combined with nanoparticles. Drug Deliv 24:83–91.

Pardelke J, Strehmer DM, Schrödl N, et al. (2011). Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines. Int J Pharmaceut 420:93–100.

Pardhi VP, Verma T, Flora SJS, et al. (2019). Nanocrystals: an overview of fabrication, characterization and therapeutic applications in drug delivery. CPD 24:5129–46.

Parmentier J, Tan EH, Low A, Muller RH, Moschwitzer JP. (2012). Nanocrystals: versatility for modern pharmaceuticals. Wires Nanom Nanobi 4:1477.

Singh MK, Pooja D, Ravuri HG, et al. (2018). Fabrication of surfactant-stabilized nanosuspension of naringenin to surpass its poor physicochemical properties and low oral bioavailability. Phytomedicine 40: 48–54.

Singh B, Muller RH, Moschwitzer JP. (2013). Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size. Int J Pharm 453:126–41.

Singh B, Muller RH, Moschwitzer JP. (2013). Systematic investigation of the cavi-precipitation process for the production of ibuprofen nanocrystals. Int J Pharm 458:315–23.

Soisuwан S, Teeranachaideekul V, Wongrakpanich A, et al. (2019). Impact of uncharged and charged stabilizers on in vitro drug performances of clarithromycin nanocrystals. Eur J Pharm Biopharm 137:68–76.

Pailla SR, Talluri S, Rangaraj N, et al. (2019). Intranasal Zotepine Nanosuspension: intended for improved brain distribution in rats. Daru: journal of Faculty of Pharmacy, Tehran University of Medical Sciences.

Staedtke V, Brähler M, Müller A, et al. (2010). In vitro inhibition of fungal activity by macrophage-mediated sequestration and release of encapsulated amphotericin B nanosuspension in red blood cells. Small 6: 96–103.

Sullivan SP, Murthy N, Prausnitz MR. (2008). Minimally invasive protein delivery with rapidly dissolving polymer microneedles. Adv Mater 20: 933–8.

Tan S, Wu T, Zhang D, Zhang Z. (2015). Cell or cell membrane-based drug delivery systems. Theranostics 5:863–81.

Tuomela A, Hirvonen J, Peltonen L. (2016). Stabilizing agents for drug nanocrystals: effect on bioavailability. Pharmaceutics 8:16.

Ueda K, Iwai T, Sunazuka Y, et al. (2019). Effect of molecular weight of polysaccharide on the critical properties of amphotericin B nanosuspension. Small 6: 23.

Vora LK, Vavia PR, Larraneta E, et al. (2018). Novel nanosuspension-based dissolving microneedle arrays for transdermal delivery of a hydrophobic drug. J Interdiscip Nanomed 3:89–101.

Wang H, Xiao Y, Sang Z, et al. (2019). Development of daidzein nanosuspensions: preparation, characterization, in vitro evaluation, and pharmacokinetic analysis. Int J Pharm 566:67–76.

Wang T, Qi J, Ding N, et al. (2018). Tracking translocation of self-discriminating curcumin hybrid nanocrystals following intravenous delivery. Int J Pharm 546:10–9.
Wang YT, Wang CY, Zhao J, et al. (2017). A cost-effective method to prepare curcumin nanosuspensions with enhanced oral bioavailability. J Colloid Interf Sci 485:91–8.

Wei Q, Keck CM, Müller RH. (2018). Solidification of hesperidin nanosuspension by spray drying optimized by design of experiment (DoE). Drug Dev Ind Pharm 44:1–12.

Xie J, Luo YJ, Liu Y, et al. (2019). Novel redispersible nanosuspensions stabilized by co-processed nanocrystalline cellulose-sodium carboxymethyl starch for enhancing dissolution and oral bioavailability of baicalin. UN 14:353–69.

Yang H, Kim H, Jung S, et al. (2018). Pharmaceutical strategies for stabilizing drug nanocrystals. CPD 24:2362–74.

Yang L, Hong J, Di J, et al. (2017). 10-Hydroxycamptothecin (HCPT) nanosuspensions stabilized by mPEG1000-HCPT conjugate: high stabilizing efficiency and improved antitumor efficacy. UN 12:3681–95.

Ye XY, Patil H, Feng X, et al. (2016). Conjugation of hot-melt extrusion with high-pressure homogenization: a novel method of continuously preparing nanocrystal solid dispersions. AAPS PharmSciTech 17:78–88.

Zhai X, Lademann J, Keck CM, Müller RH. (2014). Dermal nanocrystals from medium soluble actives - physical stability and stability affecting parameters. Eur J Pharm Biopharm 88:85–91.

Zhao RS, Hollis CP, Zhang H, et al. (2011). Hybrid nanocrystals: achieving concurrent therapeutic and bioimaging functionalities toward solid tumors. Mol Pharmaceutics 8:1985–91.

Zhou YX, Fang QY, Niu BY, et al. (2018). Comparative studies on amphoterin B nanosuspensions prepared by a high pressure homogenization method and an antisolvent precipitation method. Colloid Surface B 172:372–9.

Zu YG, Sun W, Zhao XH, et al. (2014). Preparation and characterization of amorphous amphoterin B nanoparticles for oral administration through liquid antisolvent precipitation. Eur J Pharm Sci 53:109–17.